المؤلفون: Aygen, Bilgehan, Demirtürk, Neşe, Yıldız, Orhan, Çelen, Mustafa Kemal, Çelik, İlhami, Barut, Şener, Ural, Onur, Batırel, Ayşe, Şimşek, Funda, Aşan, Ali, Ersöz, Gülden, Türker, Nesrin, Bilgin, Hüseyin, Kınıklı, Sami, Karakeçili, Faruk, Zararsız, Gökmen

المساهمون: Bursa Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı., Mıstık, Reşit, DFY-3761-2022, 6602564624

مصطلحات موضوعية: Gastroenterology & hepatology, Chronic hepatitis c, Hcv genotypes 1 and 4, Ombitasvir, Paritaprevir, Dasabuvir, Real-world effectiveness, Sustained virological response, Ritonavir plus ribavirin, Antiviral therapy, Hcv, Abt-450/r-ombitasvir, Multicenter, Paritaprevir/ritonavir/ombitasvir, Retreatment, 2-Naphthylamine, Adult, Aged, 80 and over, Anilides, Antiviral agents, Cyclopropanes, Databases, Factual, Drug therapy, combination, Female, Genotype, Hepacivirus, Hepatitis C

الوصف: Bu çalışma, 15-16, Mart 2019 tarihlerinde İstanbul[Türkiye]’de düzenlenen AASLD - TASL Connect Regional Meeting Kongresi‘nde bildiri olarak sunulmuştur. ; Background/Aims: mbitasvir/paritaprevir/ritonavir (OMV/PTV/r) +/- dasabuvir (DSV) +/- ribavirin (RBV) combination has demonstrated excellent rates of sustained virologic response (SVR) and a very good safety profile in patients with the chronic hepatitis C virus (HCV) genotype 1 or 4 infections. We aimed to investigate the effectiveness and safety of OMV/PTV/r +/- DSV +/- RBV combination regimen in a real-world clinical practice.Materials and Methods: Data from HCV genotype 1 and 4 patients treated with OMV/PTV/r +/- DSV +/- RBV (n=862) in 34 centers across Turkey between April 1, 2017 and August 31, 2018 were recorded in a large national database. Demographic, clinical, and virologic data were analyzed.Results: The mean age of the patients was 55.63, and 430 patients (49.9%) were male. The majority had HCV genotype 1b infection (77.3%), and 66.2% were treatment-naive. Non-cirrhosis was present at baseline in 789 patients (91.5%). SVR12 rate was 99.1% in all patients. Seven patients had virologic failure. No significant differences were observed in SVR12 according to HCV genotypes. HCV RNA was undetectable at treatment week 4 in 90.9%, at treatment week 8 in 98.5%, and at the end of treatment (EOT) in 98.9%. SVR12 ratio was significantly higher in the non-cirrhotic patients compared to that in the compensated cirrhotic patients. Rates of adverse events (AEs) in the patients was 59.7%.Conclusion: The present real-life data of Turkey for the OBV/PTV/r +/- DSV +/- RBV treatment of patients with HCV genotype 1b, 1a, or 4 infection from 862 patients demonstrated high efficacy and a safety profile. ; AASLD ; TASL

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Turkish Journal of Gastroenterology; Yurt içi; Sanayi; Aygen, B. vd. (2020). "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience". Turkish Journal of Gastroenterology, 31(4), 305-317.; https://turkjgastroenterol.org/en/real-world-efficacy-safety-and-clinical-outcomes-of-ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-combination-therapy-in-patients-with-hepatitis-c-virus-genotypeTest-1-or-4-infection-the-turkey-experience-experience-136659; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236650Test/; https://hdl.handle.net/11452/38946Test; 000535263200004; 2-s2.0-85084787334; 305; 317; 31; https://doi.org/10.5152/tjg.2020.19197Test

الإتاحة: https://doi.org/10.5152/tjg.2020.19197Test
https://hdl.handle.net/11452/38946Test
https://turkjgastroenterol.org/en/real-world-efficacy-safety-and-clinical-outcomes-of-ombitasvir-paritaprevir-ritonavir-dasabuvir-ribavirin-combination-therapy-in-patients-with-hepatitis-c-virus-genotypeTest-1-or-4-infection-the-turkey-experience-experience-136659
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236650Test/

المساهمون: Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı., orcid:0000-0002-9802-0880, Temel, Şehime, AAG-8385-2021, 6507885442

مصطلحات موضوعية: Variants, Azoospermia, Genetics & heredity, Adult, Alleles, Animals, Cell cycle checkpoints, Homozygote, Humans, Infertility, male, Meiosis, Mice, Mutation, Phenotype, Proteins, Spermatogenesis, Spermatozoa, Testis, Turkey, Whole exome sequencing, Male Infertility, Y Chromosome, Meiosis 1 arresting protein, mouse, Protein, Allele, Article, Cryptozoospermia, Disease severity

الوصف: Bu çalışmada 26 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. ; Male infertility affects similar to 7% of men, but its causes remain poorly understood. The most severe form is non-obstructive azoospermia (NOA), which is, in part, caused by an arrest at meiosis. So far, only a few validated disease-associated genes have been reported. To address this gap, we performed whole-exome sequencing in 58 men with unexplained meiotic arrest and identified the same homozygous frameshift variant c.676dup (p.Trp226LeufsTer4) in M1AP, encoding meiosis 1 associated protein, in three unrelated men. This variant most likely results in a truncated protein as shown in vitro by heterologous expression of mutant M1AP. Next, we screened four large cohorts of infertile men and identified three additional individuals carrying homozygous c.676dup and three carrying combinations of this and other likely causal variants in M1AP. Moreover, a homozygous missense variant, c.1166C>T (p.Pro389Leu), segregated with infertility in five men from a consanguineous Turkish family. The common phenotype between all affected men was NOA, but occasionally spermatids and rarely a few spermatozoa in the semen were observed. A similar phenotype has been described for mice with disruption of M1ap. Collectively, these findings demonstrate that mutations in M1AP are a relatively frequent cause of autosomal recessive severe spermatogenic failure and male infertility with strong clinical validity. ; National Institutes of Health ; NIH Office of the Director ; Eunice Kennedy Shriver National Institute of Child Health and Human Development ; Deutsche Forschungsgemeinschaft

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; KUAP(T)-2014/36; American Journal of Human Genetics; Yurt içi; Yurt dışı; Sanayi; Wyrwoll, M. J. vd. (2020). "Bi-allelic mutations in M1AP are a frequent cause of meiotic arrest and severely impaired spermatogenesis leading to male infertility". American Journal of Human Genetics, 107(2), 342-351.; https://doi.org/10.1016/j.ajhg.2020.06.010Test; https://www.sciencedirect.com/science/article/pii/S0002929720301981Test; http://hdl.handle.net/11452/30096Test; 000558491800014; 2-s2.0-85088861386; 341; 351; 107

الإتاحة: https://doi.org/10.1016/j.ajhg.2020.06.010Test
http://hdl.handle.net/11452/30096Test
https://www.sciencedirect.com/science/article/pii/S0002929720301981Test

المؤلفون: Serter Kocaoğlu, Sema

المساهمون: Bursa Uludağ Üniversitesi/Tıp Fakültesi/Histoloji ve Embriyoloji Anabilim Dalı., orcid:0000-0001-5757-8450, orcid:0000-0003-3463-7483, Gök, Duygu Yurtseven, Minbay, Zehra, Ezigör, Özhan, ABE-5128-2020, ABC-1475-2020, AAW-4867-2021, 57193760779, 8220935200, 6603109907

مصطلحات موضوعية: Glutamate, Nesfatin-1, C-Fos, Hypothalamus, Rat, Blood-brain-barrier, Subunit messenger-RNAs, Receptor subunits, Ultrastructural-localization, Satiety molecule, Kainic acid, Expression, Kainate, Activation, Neurosciences & neurology, Neurosciences, Nucleobindin, Pyroglutamyl-Histidyl-Glycine, DNA-Binding Proteins, 6 cyano 7 nitro 2,3 quinoxalinedione, AMPA receptor agonist, N methyl dextro aspartic acid receptor, N methyl dextro aspartic acid receptor stimulating agent, Nesfatin 1, Neurotransmitter, Unclassified drug, Adult, Animal experiment, Animal model, Animal tissue

الوصف: Nesfatin-1, identified as an anorexigenic peptide, regulates the energy metabolism by suppressing food intake. The majority of nesfatin-1-synthesizing neurons are concentrated in various hypothalamic nuclei, especially in the supraoptic (SON), arcuate (ARC) and paraventricular nuclei (PVN). We tested the hypothesis that the glutamatergic system regulates nesfatin-1 neurons through glutamate receptors. Therefore, the first aim of the proposed studies was to examine effects of different glutamate agonists in the activation of nesfatin-1 neurons using c-Fos double immunohistochemical labeling. Experimental groups were formed containing male and female rats which received intraperitoneal injections of glutamate agonists kainic acid, alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-D-aspartate (NMDA) while the control rats received vehicle. The significant increase in the number of c-Fos-expressing nesfatin-1 neurons after agonist injections were observed both in female and male subjects and some of these effects were found to be sexually dimorphic. In addition, treatment with specific glutamate antagonists 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) or dizocilpine (MK-801) before each of the three agonist injections caused a statistically significant reduction in the number of activated nesfatin-1 neurons in the hypothalamic nuclei including supraoptic, paraventricular and arcuate nuclei. The second aim of the study was to determine the expression of glutamate receptor subunit proteins in the nesfatin-1 neurons by using a double immunofluorescence technique. The results showed that the glutamate receptor subunits, which may form homomeric or heteromeric functional receptor channels, were expressed in the nesfatin-1 neurons. In conclusion, the results of this study suggest that nesfatin-1 neurons respond to glutamatergic signals in the form of neuronal activation and that the glutamate receptors that are synthesized by nesfatin-1 neurons may participate in the glutamatergic regulation of ...

وصف الملف: application/pdf

العلاقة: TÜBİTAK; Makale - Uluslararası Hakemli Dergi; Brain Sciences; Yurt içi; Yurtseven, D. G. vd. (2020). "Immunohistochemical evidence for glutamatergic regulation of nesfatin-1 neurons in the rat hypothalamus". Brain Sciences, 10(9).; https://doi.org/10.3390/brainsci10090630Test; https://www.mdpi.com/2076-3425/10/9/630Test; http://hdl.handle.net/11452/30041Test; 000580138200001; 2-s2.0-85090779765; 10

الإتاحة: https://doi.org/10.3390/brainsci10090630Test
http://hdl.handle.net/11452/30041Test
https://www.mdpi.com/2076-3425/10/9/630Test

المساهمون: Bursa Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Genetik Anabilim Dalı., orcid:0000-0002-9802-0880, Temel, Şehime, AAG-8385-2021, 6507885442

مصطلحات موضوعية: Variants, Azoospermia, Genetics & heredity, Adult, Alleles, Animals, Cell cycle checkpoints, Homozygote, Humans, Infertility, male, Meiosis, Mice, Mutation, Phenotype, Proteins, Spermatogenesis, Spermatozoa, Testis, Turkey, Whole exome sequencing, Male Infertility, Y Chromosome, Meiosis 1 arresting protein, mouse, Protein, Allele, Article, Cryptozoospermia, Disease severity

الوصف: Bu çalışmada 26 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. ; Male infertility affects similar to 7% of men, but its causes remain poorly understood. The most severe form is non-obstructive azoospermia (NOA), which is, in part, caused by an arrest at meiosis. So far, only a few validated disease-associated genes have been reported. To address this gap, we performed whole-exome sequencing in 58 men with unexplained meiotic arrest and identified the same homozygous frameshift variant c.676dup (p.Trp226LeufsTer4) in M1AP, encoding meiosis 1 associated protein, in three unrelated men. This variant most likely results in a truncated protein as shown in vitro by heterologous expression of mutant M1AP. Next, we screened four large cohorts of infertile men and identified three additional individuals carrying homozygous c.676dup and three carrying combinations of this and other likely causal variants in M1AP. Moreover, a homozygous missense variant, c.1166C>T (p.Pro389Leu), segregated with infertility in five men from a consanguineous Turkish family. The common phenotype between all affected men was NOA, but occasionally spermatids and rarely a few spermatozoa in the semen were observed. A similar phenotype has been described for mice with disruption of M1ap. Collectively, these findings demonstrate that mutations in M1AP are a relatively frequent cause of autosomal recessive severe spermatogenic failure and male infertility with strong clinical validity. ; National Institutes of Health ; NIH Office of the Director ; Eunice Kennedy Shriver National Institute of Child Health and Human Development ; Deutsche Forschungsgemeinschaft

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; KUAP(T)-2014/36; American Journal of Human Genetics; Yurt içi; Yurt dışı; Sanayi; Wyrwoll, M. J. vd. (2020). "Bi-allelic mutations in M1AP are a frequent cause of meiotic arrest and severely impaired spermatogenesis leading to male infertility". American Journal of Human Genetics, 107(2), 342-351.; https://doi.org/10.1016/j.ajhg.2020.06.010Test; https://www.sciencedirect.com/science/article/pii/S0002929720301981Test; http://hdl.handle.net/11452/30096Test; 000558491800014; 2-s2.0-85088861386; 341; 351; 107

الإتاحة: https://doi.org/10.1016/j.ajhg.2020.06.010Test
http://hdl.handle.net/11452/30096Test
https://www.sciencedirect.com/science/article/pii/S0002929720301981Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, 6603145040, 24331130000

مصطلحات موضوعية: Oncology, Hodgkin lymphoma, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuxımab vedotın, PD-1 blockade, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic, Agents, Disease-free survival, Female, Hodgkin disease, Humans, Immunoconjugates, Male, Middle aged, Retrospective studies, Stem cell transplantation, Young adult, Brentuximab Vedotin, Hodgkin's Disease, Refractory Materials, Mycophenolate mofetil, Programmed death 1 receptor, Steroid

الوصف: "Çalışmada 32 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır” ; Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively. Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related. Conclusions: Nivolumab represents a novel option for patients with cHL ...

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Oncology; Yurt içi; Sanayi; Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.; https://doi.org/10.1093/annonc/mdx341Test; https://www.sciencedirect.com/science/article/pii/S0923753419349452Test; http://hdl.handle.net/11452/32082Test; 000411827200025; 2-s2.0-85030557671; 2496; 2502; 28; 10

الإتاحة: https://doi.org/10.1093/annonc/mdx341Test
http://hdl.handle.net/11452/32082Test
https://www.sciencedirect.com/science/article/pii/S0923753419349452Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı., Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı., Özkocaman, Vildan, Demirkaya, Metin, AAH-1854-2021, 6603145040, 24331130000

مصطلحات موضوعية: Oncology, Hodgkin lymphoma, Resistant/relapsed disease, Programmed death 1 (PD-1) blocker, Nivolumab, Brentuxımab vedotın, PD-1 blockade, Adolescent, Adult, Aged, Antibodies, Monoclonal, Antineoplastic, Agents, Disease-free survival, Female, Hodgkin disease, Humans, Immunoconjugates, Male, Middle aged, Retrospective studies, Stem cell transplantation, Young adult, Brentuximab Vedotin, Hodgkin's Disease, Refractory Materials, Mycophenolate mofetil, Programmed death 1 receptor, Steroid

الوصف: "Çalışmada 32 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır” ; Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively. Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related. Conclusions: Nivolumab represents a novel option for patients with cHL ...

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Annals of Oncology; Yurt içi; Sanayi; Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.; https://doi.org/10.1093/annonc/mdx341Test; https://www.sciencedirect.com/science/article/pii/S0923753419349452Test; http://hdl.handle.net/11452/32082Test; 000411827200025; 2-s2.0-85030557671; 2496; 2502; 28; 10

الإتاحة: https://doi.org/10.1093/annonc/mdx341Test
http://hdl.handle.net/11452/32082Test
https://www.sciencedirect.com/science/article/pii/S0923753419349452Test

المؤلفون: Altay, Canan, Seçil, Mustafa, Demir, Tevfik, Atik, Tahir, Akıncı, Gülçin, Kutbay, Nilüfer Özdemir, Temeloğlu, Ela Keskin, Şimşir, Ilgin Yıldırım, Özışık, Seçil, Demir, Leyla, Tuna, Emine Burçin, Aytaç, Hasibe, Onay, Hüseyin, Akıncı, Barış

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Endokrinoloji Anabilim Dalı., orcid:0000-0002-1684-1053, Eren, Erdal, AAM-1734-2020, AAH-1155-2021, 36113153400

مصطلحات موضوعية: Radiology, nuclear medicine & medical imaging, Congenital generalized lipodystrophy, Familial partial lipodystrophy, Severe insulin-resistance, Body-fat distribution, Gene-expression, Regional differences, Ptrf mutationsi, Identification, Heterogeneity, Deficiency, Adipose tissue, Adolescent, Adult, Child, Diagnosis, differential, Female, Humans, Lipodystrophy, Magnetic resonance imaging, Male, Middle aged, Whole body Imaging, Young adult, Metreleptin, Acquired Partial Lipodystrophy, Caveolin 1, Creatinine

الوصف: PURPOSE We aimed to investigate residual adipose tissue with whole-body magnetic resonance imaging to differentiate between subtypes of lipodystrophy. METHODS A total of 32 patients 12 with congenital generalized lipodystrophy [CGL], 1 with acquired generalized lipodystrophy [AGL], 12 with familial partial lipodystrophy [FPLD], and 7 with acquired partial lipodystrophy [APL]) were included. RESULTS Despite generalized loss of metabolically active adipose tissue, patients with CGL1 caused by AGPAT2 mutations had a significant amount of residual adipose tissue in the scalp, earlobes, retro-orbital region, and palms and soles. No residual adipose tissue was noted particularly in the head and neck, palms and soles in CGL2 caused by BSCL2 mutations. CGL4 caused by mutations in the PTRF gene was characterized with well-preserved retro-orbital and bone marrow fat in the absence of any visible residual adipose tissue in other areas. No residual adipose tissue was observed in AGL. Despite loss of subcutaneous fat, periarticular adipose tissue was preserved in the lower limbs of patients with FPLD. Retro-orbital adipose tissue was surprisingly preserved in APL, although they lacked head and neck fat. CONCLUSION Lipodystrophies are a heterogeneous group of disorders characterized by generalized or partial loss of adipose tissue, which can be congenital or acquired. Our results suggest that residual adipose tissue characteristics can help distinguish different subtypes of lipodystrophy.

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Diagnostic and Interventional Radiology; Yurt içi; Sanayi; Altay, C. vd. (2017). ''Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy''. Diagnostic and Interventional Radiology, 23(6), 428-434.; https://doi.org/10.5152/dir.2017.17019Test; https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test; http://hdl.handle.net/11452/30424Test; 000414273500004; 2-s2.0-85032956287; 428; 434; 23

الإتاحة: https://doi.org/10.5152/dir.2017.17019Test
http://hdl.handle.net/11452/30424Test
https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test

المؤلفون: Altay, Canan, Seçil, Mustafa, Demir, Tevfik, Atik, Tahir, Akıncı, Gülçin, Kutbay, Nilüfer Özdemir, Temeloğlu, Ela Keskin, Şimşir, Ilgin Yıldırım, Özışık, Seçil, Demir, Leyla, Tuna, Emine Burçin, Aytaç, Hasibe, Onay, Hüseyin, Akıncı, Barış

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Endokrinoloji Anabilim Dalı., orcid:0000-0002-1684-1053, Eren, Erdal, AAM-1734-2020, AAH-1155-2021, 36113153400

مصطلحات موضوعية: Radiology, nuclear medicine & medical imaging, Congenital generalized lipodystrophy, Familial partial lipodystrophy, Severe insulin-resistance, Body-fat distribution, Gene-expression, Regional differences, Ptrf mutationsi, Identification, Heterogeneity, Deficiency, Adipose tissue, Adolescent, Adult, Child, Diagnosis, differential, Female, Humans, Lipodystrophy, Magnetic resonance imaging, Male, Middle aged, Whole body Imaging, Young adult, Metreleptin, Acquired Partial Lipodystrophy, Caveolin 1, Creatinine

الوصف: PURPOSE We aimed to investigate residual adipose tissue with whole-body magnetic resonance imaging to differentiate between subtypes of lipodystrophy. METHODS A total of 32 patients 12 with congenital generalized lipodystrophy [CGL], 1 with acquired generalized lipodystrophy [AGL], 12 with familial partial lipodystrophy [FPLD], and 7 with acquired partial lipodystrophy [APL]) were included. RESULTS Despite generalized loss of metabolically active adipose tissue, patients with CGL1 caused by AGPAT2 mutations had a significant amount of residual adipose tissue in the scalp, earlobes, retro-orbital region, and palms and soles. No residual adipose tissue was noted particularly in the head and neck, palms and soles in CGL2 caused by BSCL2 mutations. CGL4 caused by mutations in the PTRF gene was characterized with well-preserved retro-orbital and bone marrow fat in the absence of any visible residual adipose tissue in other areas. No residual adipose tissue was observed in AGL. Despite loss of subcutaneous fat, periarticular adipose tissue was preserved in the lower limbs of patients with FPLD. Retro-orbital adipose tissue was surprisingly preserved in APL, although they lacked head and neck fat. CONCLUSION Lipodystrophies are a heterogeneous group of disorders characterized by generalized or partial loss of adipose tissue, which can be congenital or acquired. Our results suggest that residual adipose tissue characteristics can help distinguish different subtypes of lipodystrophy.

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; Diagnostic and Interventional Radiology; Yurt içi; Sanayi; Altay, C. vd. (2017). ''Determining residual adipose tissue characteristics with MRI in patients with various subtypes of lipodystrophy''. Diagnostic and Interventional Radiology, 23(6), 428-434.; https://doi.org/10.5152/dir.2017.17019Test; https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test; http://hdl.handle.net/11452/30424Test; 000414273500004; 2-s2.0-85032956287; 428; 434; 23

الإتاحة: https://doi.org/10.5152/dir.2017.17019Test
http://hdl.handle.net/11452/30424Test
https://www.dirjournal.org/en/determining-residual-adipose-tissue-characteristics-with-mri-in-patients-with-various-subtypes-of-lipodystrophy-131769Test

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı., Mıstık, Reşit, 6602564624

مصطلحات موضوعية: Infectious diseases, Baseline resistance, Hepatitis C virus, Mutation, Protease inhibitors, Genotype 1, Pegylated interferon, Antiviral agents, Virus genotypes, Ribavirin, Telaprevir, Simeprevir, Infection, Polymorphisms, Retreatment, Adult, Aged, 80 and over, Drug resistance, viral, Female, Genotype, Hepacivirus, Hepatitis C, chronic, Humans, Male, Middle aged, Oligopeptides, Proline

الوصف: Çalışmada 21 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır. ; Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals. Materials and methods: 178 antiviral-naive patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of these patients were analyzed. Results: In 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause drug resistance was identified. The most frequently detected mutation pattern was T54S while R109K was the second most frequently detected. Following a more general examination of the patients studied, telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and amongst two V55A mutations following treatment with TVR, while no response to treatment was detected in a patient with a R55K mutation. Conclusion: We are of the opinion that drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for pre-treatment natural resistance and which mutations are responsible for the viral breakthrough that may develop during the treatment. ; Kocaeli Üniversitesi Bilimsel Araştırma Projeleri Bölümü ; Türk Klinik Mikrobiyoloji ve Enfeksiyon Hastalıkları Derneği

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; International Journal of Infectious Diseases; Yurt içi; Yurt dışı; Sanayi; Altunok, E. S. vd. (2016). "Protease inhibitors drug resistance mutations in Turkish patients with chronic hepatitis C". ed. Petersen, E. ve Denmark, A. International Journal of Infectious Diseases, 50, 1-5.; https://doi.org/10.1016/j.ijid.2016.07.003Test; https://www.sciencedirect.com/science/article/pii/S1201971216311109Test; http://hdl.handle.net/11452/29837Test; 000388326300001; 2-s2.0-84979254596; 50

الإتاحة: https://doi.org/10.1016/j.ijid.2016.07.003Test
http://hdl.handle.net/11452/29837Test
https://www.sciencedirect.com/science/article/pii/S1201971216311109Test

المؤلفون: Sayan, Murat, Sargın, Fatma, İnan, Dilara, Sevgi, Dilek Y., Çelikbaş, Aysel K., Yaşar, Kadriye, Kaptan, Figen, Kutlu, Selda, Fışgın, Nuriye T., İnci, Ayşe, Ceran, Nurgül, Karaoğlan, İlkay, Çağatay, Atahan, Çelen, Mustafa K., Koruk, Suda T., Ceylan, Bahadir, Yıldırmak, Taner, Korten, Volkan, Willke, Ayşe

المساهمون: Uludağ Üniversitesi/Tıp Fakültesi/Enfeksiyon Hastalıkları Anabilim Dalı., Akalın, Halis, AAU-8952-2020, 57207553671

مصطلحات موضوعية: Immunology, Infectious diseases, Virology, HIV-1-infected persons, Surveillance, Therapy, Recommendations, Epidemiology, Update, Adult, Anti-HIV agents, CD4 lymphocyte count, Drug resistance, viral, Female, Gene expression, HIV infections, HIV protease, HIV protease inhibitors, HIV reverse transcriptase, HIV-1, Humans, Male, Mutation, Prevalence, Reverse transcriptase inhibitors, RNA, Turkey, Pol Genes, Human Immunodeficiency Virus 1

الوصف: HIV-1 replication is rapid and highly error-prone. Transmission of a drug-resistant HIV-1 strain is possible and occurs within the HIV-1-infected population. In this study, we aimed to determine the prevalence of transmitted drug resistance mutations (TDRMs) in 1,306 newly diagnosed untreated HIV-1-infected patients from 21 cities across six regions of Turkey between 2010 and 2015. TDRMs were identified according to the criteria provided by the World Health Organization's 2009 list of surveillance drug resistance mutations. The HIV-1 TDRM prevalence was 10.1% (133/1,306) in Turkey. Primary drug resistance mutations (K65R, M184V) and thymidine analogue-associated mutations (TAMs) were evaluated together as nucleos(t)ide reverse transcriptase inhibitor (NRTI) mutations. NRTI TDRMs were found in 8.1% (107/1,306) of patients. However, TAMs were divided into three categories and M41L, L210W, and T215Y mutations were found for TAM1 in 97 (7.4%) patients, D67N, K70R, K219E/Q/N/R, T215F, and T215C/D/S mutations were detected for TAM2 in 52 (3.9%) patients, and M41L + K219N and M41L + T215C/D/S mutations were detected for the TAM1 + TAM2 profile in 22 (1.7%) patients, respectively. Nonnucleoside reverse transcriptase inhibitor-associated TDRMs were detected in 3.3% (44/1,306) of patients (L100I, K101E/P, K103N/S, V179F, Y188H/L/M, Y181I/C, and G190A/E/S) and TDRMs to protease inhibitors were detected in 2.3% (30/1,306) of patients (M46L, I50V, I54V, Q58E, L76V, V82A/C/L/T, N83D, I84V, and L90M). In conclusion, long-term and large-scale monitoring of regional levels of HIV-1 TDRMs informs treatment guidelines and provides feedback on the success of HIV-1 prevention and treatment efforts.

وصف الملف: application/pdf

العلاقة: Makale - Uluslararası Hakemli Dergi; AIDS Research and Human Retroviruses; Yurt içi; Yurt dışı; Sanayi; Sayan, M. vd. (2016). "HIV-1 transmitted drug resistance mutations in newly diagnosed antiretroviral-naive patients in Turkey". AIDS Research and Human Retroviruses, 32(1), 26-31.; https://doi.org/10.1089/aid.2015.0110Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692107Test/; http://hdl.handle.net/11452/29626Test; 000367335100005; 2-s2.0-84954092536; 26; 31; 32

الإتاحة: https://doi.org/10.1089/aid.2015.0110Test
http://hdl.handle.net/11452/29626Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4692107Test/